Shlomo Raz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shlomo Raz has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Seth A. Cohen
Pelvic Medicine and Reconstructive Surgery
3 shared publicationsA. Lenore Ackerman
Urologic Reconstruction, Urodynamics, and Female Urology, Cedars-Sinai Medical Center
2 shared publications- Larissa V. Rodriguez
The Geffen School of Medicine at UCLA
2 shared publications Lisa Rogo-Gupta
Division of Pelvic Medicine & Reconstructive Surgery, Department of Urology, University of California Los Angeles, 200 Medical Plaza, Suite 140, Los Angeles, CA 90095, USA
2 shared publications- Andrea Staack
Department of Urology, Loma Linda University Health, USA
1 shared publication - Anne Lenore Ackerman
Affiliation Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America
1 shared publication
Latest Publications
- 30 March 2017
- Published by Springer Nature
- p. 249-291
Native Tissue Repair After Failed Synthetic Materials
- 30 March 2017
- Published by Springer Nature
- p. 249-291
Native Tissue Repair After Failed Synthetic Materials
- 21 December 2016
- Published by Springer Nature
- p. 79-88
Neurogenic Bladder Obstruction
- 21 September 2016
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (2) , 519-523
Comparison of Times to Ureteral Efflux after Administration of Sodium Fluorescein and Phenazopyridine
There is currently a national shortage of indigo carmine. In efforts to identify the most efficient aid for visualizing ureteral efflux intraoperatively we investigated the time to excretion of phenazopyridine vs a newly identified alternative, sodium fluorescein. We analyzed prospectively collected data on a cohort of women who underwent pelvic reconstructive surgery in 2015. Per provider preference patterns a number of patients were administered 200 mg phenazopyridine orally with a sip of water 1 hour prior to the start of operative time. Other patients were given 0.5 ml 10% sodium fluorescein intravenously in the operating room. In all cases time was measured between the administration of the agent and the visualization of color changes consistent with agent efflux in an indwelling catheter, which was placed at the start of the operation. Differences in excretion times between the groups were compared with the Wilcoxon rank sum test. Seven women received phenazopyridine and 5 received sodium fluorescein. Mean excretion time was significantly longer in the phenazopyridine group compared to the sodium fluorescein group (81.9 vs 5.1 minutes, p = 0.0057). Median excretion time for phenazopyridine was 70 minutes (range 59 to 127) and for sodium fluorescein it was 5 minutes (range 3 to 9). Sodium fluorescein is excreted significantly faster in the operating room compared to phenazopyridine. Depending on the cost of these agents at an institution, in addition to the desire to decrease operative time, this may impact practice patterns and agent selection.
- 21 September 2016
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (2) , 519-523
Comparison of Times to Ureteral Efflux after Administration of Sodium Fluorescein and Phenazopyridine
There is currently a national shortage of indigo carmine. In efforts to identify the most efficient aid for visualizing ureteral efflux intraoperatively we investigated the time to excretion of phenazopyridine vs a newly identified alternative, sodium fluorescein. We analyzed prospectively collected data on a cohort of women who underwent pelvic reconstructive surgery in 2015. Per provider preference patterns a number of patients were administered 200 mg phenazopyridine orally with a sip of water 1 hour prior to the start of operative time. Other patients were given 0.5 ml 10% sodium fluorescein intravenously in the operating room. In all cases time was measured between the administration of the agent and the visualization of color changes consistent with agent efflux in an indwelling catheter, which was placed at the start of the operation. Differences in excretion times between the groups were compared with the Wilcoxon rank sum test. Seven women received phenazopyridine and 5 received sodium fluorescein. Mean excretion time was significantly longer in the phenazopyridine group compared to the sodium fluorescein group (81.9 vs 5.1 minutes, p = 0.0057). Median excretion time for phenazopyridine was 70 minutes (range 59 to 127) and for sodium fluorescein it was 5 minutes (range 3 to 9). Sodium fluorescein is excreted significantly faster in the operating room compared to phenazopyridine. Depending on the cost of these agents at an institution, in addition to the desire to decrease operative time, this may impact practice patterns and agent selection.
- Open Access
- 1 August 2016
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 42 (4) , 640-644
Are syntetic slings safe? Opinion: No
SMUS are now the standard of care and the most commonly performed procedure for the treatment of SUI worldwide. Multiple level one randomized trials have demonstrated equivalent outcomes for SMUS to Burch colposuspension and autologous fascial slings (2). In addition to their ease of use, SMUS provide faster operative times, reduced post-operative morbidity, faster resumption of normal activity, and reduced cost (3). Patient satisfaction with the procedures has been quite high (4) with comparable durability to the older techniques.
- 1 August 2016
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 42 (4) , 640-644
Open AccessAre syntetic slings safe? Opinion: No
SMUS are now the standard of care and the most commonly performed procedure for the treatment of SUI worldwide. Multiple level one randomized trials have demonstrated equivalent outcomes for SMUS to Burch colposuspension and autologous fascial slings (2). In addition to their ease of use, SMUS provide faster operative times, reduced post-operative morbidity, faster resumption of normal activity, and reduced cost (3). Patient satisfaction with the procedures has been quite high (4) with comparable durability to the older techniques.
- Open Access
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Urology
- Vol. 5 (1) , 11
Use of synthetic grafts in pelvic reconstruction: A path of continued discovery
Use of synthetic grafts in pelvic reconstruction: A path of continued discovery
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Urology
- Vol. 5 (1) , 11
Open AccessUse of synthetic grafts in pelvic reconstruction: A path of continued discovery
Use of synthetic grafts in pelvic reconstruction: A path of continued discovery
- 18 September 2014
- Published by Springer Nature
- p. 145-163
Vaginal Fistula Repairs
- 1 November 2013
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 19 (6) , 352-355
Long-Term Symptom Improvement and Overall Satisfaction After Prolapse and Incontinence Graft Removal
Objectives We report long-term symptom improvements and overall satisfaction in patients after removal of grafts used in pelvic reconstruction in a tertiary referral center. Methods We analyzed patients who underwent graft removal for treatment of related complications and who were followed for at least 2 years. Symptoms were determined by patient self-assessment questionnaires. Results Seventy-nine patients underwent partial or complete graft removal from 2005 to 2011 and met inclusion criteria. The mean follow-up time was 4.0 years (median, 3.4 years; range, 2.0–7.6 years). Forty-seven percent (37 patients) had implants for both prolapse and incontinence, 40% (32 patients) had incontinence implants only, and 13% (10 patients) had prolapse implants only. Thirty percent of those with both implants presented with multiple symptoms compared to 50% of those with prolapse implants and 44% of those with incontinence implants only. At follow-up, 75% (56 patients) reported that their symptoms were better and 15% (11 patients) reported that their symptoms were worse. Of patients who underwent graft removal for pain alone, 74% (17 patients) improved whereas17% (4 patients) were worse. When asked about spending the rest of their lives with their current symptoms, 49% (38 patients) reported positively whereas 44% (34 patients) reported negatively. Forty-one patients underwent one or more additional treatments. Conclusions Graft-related complications are often treated with surgical excision. In a cohort of 79 patients in whom implants were removed an average of 4 years earlier, 75% still report symptom improvement and 49% report good quality of life. However, many patients still feel dissatisfied and sought additional treatment during long-term follow-up. These data can be used to counsel patients considering removal of pelvic reconstruction grafts.
- 1 November 2013
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 19 (6) , 352-355
Long-Term Symptom Improvement and Overall Satisfaction After Prolapse and Incontinence Graft Removal
Objectives We report long-term symptom improvements and overall satisfaction in patients after removal of grafts used in pelvic reconstruction in a tertiary referral center. Methods We analyzed patients who underwent graft removal for treatment of related complications and who were followed for at least 2 years. Symptoms were determined by patient self-assessment questionnaires. Results Seventy-nine patients underwent partial or complete graft removal from 2005 to 2011 and met inclusion criteria. The mean follow-up time was 4.0 years (median, 3.4 years; range, 2.0–7.6 years). Forty-seven percent (37 patients) had implants for both prolapse and incontinence, 40% (32 patients) had incontinence implants only, and 13% (10 patients) had prolapse implants only. Thirty percent of those with both implants presented with multiple symptoms compared to 50% of those with prolapse implants and 44% of those with incontinence implants only. At follow-up, 75% (56 patients) reported that their symptoms were better and 15% (11 patients) reported that their symptoms were worse. Of patients who underwent graft removal for pain alone, 74% (17 patients) improved whereas17% (4 patients) were worse. When asked about spending the rest of their lives with their current symptoms, 49% (38 patients) reported positively whereas 44% (34 patients) reported negatively. Forty-one patients underwent one or more additional treatments. Conclusions Graft-related complications are often treated with surgical excision. In a cohort of 79 patients in whom implants were removed an average of 4 years earlier, 75% still report symptom improvement and 49% report good quality of life. However, many patients still feel dissatisfied and sought additional treatment during long-term follow-up. These data can be used to counsel patients considering removal of pelvic reconstruction grafts.
- Open Access
- 1 September 2012
- Published by SAGE Publications in Women's Health
- Vol. 8 (5) , 557-566
Surgical Options for Apical Prolapse Repair
Pelvic organ prolapse is a common medical condition that affects the quality of life of many women. Approximately 50% of parous women have pelvic organ prolapse and the lifetime risk for surgical intervention is 6.7% at the age of 80 years. In the USA, the number of women at risk for symptomatic prolapse is increasing, which is consistent with the recent increase in the overall number of prolapse and incontinence procedures being performed. Although prolapse is usually multicompartmental and isolated defects are rare, the apical compartment deserves special attention because apical support is integral to a durable prolapse repair. Since many women may initially present to their primary care physicians, all members of the medical community should have a basic understanding of the diagnosis and treatment for apical prolapse.
- 1 September 2012
- Published by SAGE Publications in Women's Health
- Vol. 8 (5) , 557-566
Open AccessSurgical Options for Apical Prolapse Repair
Pelvic organ prolapse is a common medical condition that affects the quality of life of many women. Approximately 50% of parous women have pelvic organ prolapse and the lifetime risk for surgical intervention is 6.7% at the age of 80 years. In the USA, the number of women at risk for symptomatic prolapse is increasing, which is consistent with the recent increase in the overall number of prolapse and incontinence procedures being performed. Although prolapse is usually multicompartmental and isolated defects are rare, the apical compartment deserves special attention because apical support is integral to a durable prolapse repair. Since many women may initially present to their primary care physicians, all members of the medical community should have a basic understanding of the diagnosis and treatment for apical prolapse.